More Videos
SPECIAL REPORT
MOST SHARED
- Future of Marketing
- Dow Up Over 100 After G20 Stimulus Pledge
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Oil Tomorrow
- Dow Industrials at New Highs—But Other Indices Lag
- Obama Says Will Raise Currency Issue with China
- Priceline Crushes Profit Forecasts; Shares Jump
- Trial of Ex-Bear Stearns Managers Goes to Jury
- A Year on, China's Stimulus Postpones its Problems
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Obama Says Will Raise Currency Issue with China
- Look Ahead: 'Risk On' Attitude Could Fuel Rally Further
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
- Do You Know Your Coca-Cola Myths?
- Electronic Arts Beats Street, Announces 1,500 Job Cuts
- Time Is Here to Look at Overseas Stocks: Bill Gross
- Home Prices Start to Stabilize In the US as Sales Pick Up
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term" and he's cutting his price target from $43 to $40.
On the one hand, Patel writes that MRK [MRK
Loading...
()
]"is among the most innovative and best managed companies in the sector." But on the other hand, he wants to see evidence of long-term revenue growth prospects, does not see near-term earnings upside and believes that sales of the company's cervical cancer vaccine Gardasil could be "roughly flat" between the first quarter and the second quarter. Merck reports earnings on July 21st.
Specifically, Patel is slashing his second-quarter Gardasil sales estimate from $380 million to $300 million. "We're nervous on this front," he wrote in the research note to clients. Merck sold $293 million worth of the the vaccine in the first quarter. Patel's basing his forecast on data from IMS Health [RX
Loading...
()
]which monitors prescription trends for the industry and Wall Street. Patel points out that MRK has cautioned analysts in the past from relying on IMS' numbers for Gardasil to build their models, but he adds that over the past year the IMS data has been pretty darn close to the actual reported sales number.
On the plus side, though, Patel says his Q2 Gardasil sales projection assumes the product will have had its best sales month ever in June. Maybe that's due to pre-back-to-school buying or stockpiling of the shots. He also notes that Merck's new diabetes drugs Januvia and Janumet remain solid growth drivers and that sales of the embattled cholesterol drugs Vytorin and Zetia, which MRK shares with Schering-Plough[SGP
Loading...
()
], have stabilized over the past two-and-a-half months. But in addition to Gardasil, Patel--and many other analysts, for that matter--is also concerned about falling prescriptions for MRK's top-selling drug, Singulair, for asthma/allergies in the wake of reports about a potential suicide risk.
Merck recently suffered a regulatory setback when the FDA delayed a decision on whether to approve Gardasil for older women. But it got a competitive boost when GlaxoSmithKline [GSK
Loading...
()
]announced last month that it's pushing out the timeline for potential approval of its similar vaccine, Cervarix. Merck is also moving ahead with plans to file for the FDA OK to sell Gardasil for young men and boys who can carry the sexually-transmitted virus that's the leading cause of cervical cancer.
UBS has done investment banking for MRK and makes a market in the stock.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes